![B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-020-0734-z/MediaObjects/41375_2020_734_Fig1_HTML.png)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
![Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41392-021-00868-x/MediaObjects/41392_2021_868_Fig1_HTML.png)
Emerging new therapeutic antibody derivatives for cancer treatment | Signal Transduction and Targeted Therapy
![Cancers | Free Full-Text | BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma | HTML Cancers | Free Full-Text | BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma | HTML](https://www.mdpi.com/cancers/cancers-12-01473/article_deploy/html/images/cancers-12-01473-g001.png)
Cancers | Free Full-Text | BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma | HTML
![Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram](https://www.researchgate.net/publication/342042028/figure/tbl2/AS:903665472786435@1592462046938/Summary-clinical-study-results-of-anti-BCMA-ADC-BiTE-and-bispecific-antibodies.png)
Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram
CD269 (BCMA) Antibody, anti-human, REAfinity™ | Recombinant antibodies | MACS Antibodies | Products | Miltenyi Biotec | Suomi
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e2cdb767-eb9f-439b-b36d-d44a6decee35/ctm2346-gra-0001-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. - Abstract - Europe PMC Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6582283/bin/10.1177_2040620719854171-fig3.jpg)
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. - Abstract - Europe PMC
![Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610817300168-fx1.jpg)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect
![Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond | Journal of Hematology & Oncology | Full Text Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-021-01109-y/MediaObjects/13045_2021_1109_Fig1_HTML.png)
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond | Journal of Hematology & Oncology | Full Text
![Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma - eBioMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/87cb7e0d-8245-482e-bbbd-1c1f25355e6c/gr1_lrg.jpg)